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Open access under CC BY-NC-ND liNoriaki Emoto, MD PhD, is a Professor
at the Department of Internal Medicine
at Kobe University Graduate School of
Medicine and at Kobe Pharmaceutical Uni-
versity. After his residency as a cardiologist
in Kobe University Hospital, Japan, he
conducted his graduate studies and post-
doctoral fellowship under the supervision
of Dr. Masashi Yanagisawa in Dallas,
Texas. He won the Louis N. Katz Basic Sci-
ence Research Prizes of the AmericanHeart Association in 1994 for the molecular identiﬁcation and charac-
terization of endothelin-converting enzymes, ECE-1 and ECE-2. He
moved back to Kobe, where he leads his own laboratory as a physi-
cian–scientist. His group is staffed by two medical associate professors,
two postdoctoral fellows and medical Ph.D. students from various
countries. He is in charge of the pulmonary hypertension program in
Kobe UniversityHospital. Hismajor research interest is the translational
research of endothelin.Noriaki Emoto is Guest Editor of the Proceedings
of the Thirteenth International Conference on Endothelin, Endothelin XIIITakashi Miyauchi, MD PhD, is a Professor
of Cardiology (2003–present), Faculty of
Medicine, University of Tsukuba, Tsukuba,
Japan. He graduated from the University
of Tsukuba Medical School (1983, MD),
and also from the Graduate School of
University of Tsukuba (1990, Ph.D.). He is
a cardiologist who is also familiar with
basic sciences of pharmacology, molecular
biology, and physiology. The main themeof his research is the investigation of the physiological and pathophysio-
logical roles of vasoactive peptides including endothelin in the cardiovas-
cular systemanddiseases such as hypertension, pulmonary hypertension,
and heart failure. He published over 200 manuscripts in Lancet, Nature,
Circulation, Circulation Research, Hypertension, American Journal of
Physiology, etc. Currently, he works as a Cardiologist (Professor) at
Tsukuba University Hospital, and also works at the Life Science Center
of Tsukuba Advanced Research Alliance (TARA) at the University of
Tsukuba.Takashi Miyauchi served as Guest Editor of the Conference Pro-
ceedings of the Eighth International Conference on Endothelin
(Endothelin XIII) held in Tsukuba, Japan (Chair of ET-8: Katsutoshi Goto)..08.014
cense.Honorary ChairsTomoh Masaki, MD PhD, graduated from
the Faculty of Medicine, University of
Tokyo, in 1962. After ﬁnishing internship
training, he started his career with studies
on structural proteins of muscle at Setsuro
Ebashi's laboratory. Masaki established
alpha actinin as a new protein of muscle
and also found M-protein, and new protein
of muscle, during the late 1960s and early
1970s. He also demonstrated the existenceof several types of myosin, troponin, and or alpha actinin in different
types ofmuscles, and that these types ofmuscle protein change during dif-
ferentiation ofmuscle. Thewhole primary sequence of severalmuscle pro-
teins, including smoothmusclemyosin heavy chain,was determined inhis
laboratory. Masaki was promoted to Professor of Pharmacology, Institute
of Basic Medical Sciences, University of Tsukuba in 1975, and moved as
Professor of Pharmacology, to the Faculty of Medicine, Kyoto University,
in 1991. During this period, he focused mostly on the investigation of
smoothmuscle. In 1987 to 1990, a potent endothelial vasoconstrictor pep-
tide, endothelin, and its receptor were discovered in his laboratory in
Tsukuba. In 1997, an endothelial receptor of oxLDL (LOX-1) was found in
his laboratory at Kyoto. These vasoactive factors are thought to play impor-
tant roles in physiology and pathophysiology of vascular beds, therefore
many investigators in the world are now interested in research about
this, and new drugs have been developed from his discoveries. In 1997,
Masaki became Director of the Research Institute of the National Cardio-
vascular Center. In 2003, he assumed the position of President at Osaka
Seikei University. In 2007, Masaki was appointed Professor at Tokyo
Women's Medical University from where he retired in 2009. Professor
Masaki currently lives in Tokyo and will be celebrating his 80th birthday
in October of 2014.Katsutoshi Goto, PhD, is a Professor
Emeritus of the University of Tsukuba,
Tsukuba, Japan. He was educated at the
University of Tokyo and at West Virginia
University Medical Center, USA. He was a
Professor of Pharmacology at the Insti-
tute of Basic Medical Sciences, University
of Tsukuba. He was a member of the
team of the discovery of endothelin in
1988. After working as a Professor ofthe University of Tsukuba, he also became the Provost of Graduate
School of Comprehensive Human Sciences, University of Tsukuba.
He has been a councilor of the Japanese Pharmacological Society
was supported by grants from
59Conference Faculty, Session Chairs, and Invited Speakersfrom 1977 and a member of the American Society for Pharmacology
and Experimental Therapeutics and Federation of American
Societies for Experimental Biology from 1988. His ﬁelds of research
are pharmacology, molecular biology, and physiology of the
cardiovascular systems. The main theme of his research is the anal-
ysis of the physiological and pharmacological activity of peptides in-
cluding endothelin. From this work, he has written more than 200
papers. He was the chairman of the Eighth International Confer-
ences on Endothelin (ET-8) in 2003 at Tsukuba, Japan. After
ﬁnishing of his Professorship at the University of Tsukuba, he be-
came the Director of JST Innovation Satellite Ibaraki, Tsukuba,
Japan. Currently, he is a Professor Emeritus of the University of
Tsukuba, Tsukuba, Japan.Paul M. Vanhoutte, MD PhD, FAHA, is a
Chair Professor in the Department of
Pharmacology and Pharmacy of the Li Ka
Shing Faculty of Medicine of the Universi-
ty of Hong Kong. He obtained his M.D. de-
gree at the University of Gent, Belgium. He
has been Professor of Pharmacology at the
University of Antwerp, the Mayo Clinic,
Rochester MN, and Baylor College of Med-
icine, Houston TX. From 1992 to 2002, he
was Director of Discovery Research atPostdoctoral TrainingServier near Paris in France. Dr. Vanhoutte is Doctor honoris causa of
the Universities of Gent, Antwerp, Zurich, Montréal and Strasbourg, of
the RMIT University in Melbourne, Australia, and of the Gr. T. Popa Uni-
versity in Iasi, Romania. Dr. Vanhoutte is a Highly Cited Researcher (ISI)
in three categories: Biology & Chemistry, Pharmacology, and Clinical
Medicine. Dr. Vanhoutte is Past Chair of the Third International Confer-
ence on Endothelin (ET-3) held at Housten in 1993, Past Honorary Chair
of the Sixth International Conference on Endothelin (ET-6) held inMon-
tréal, Canada, in 1999, Past Honorary Chair of the Ninth International
Conference on Endothelin (ET-9) held in Park City, Utah, in 2005, and
Past Honorary Chair of the Twelfth International Conference on
Endothelin (ET-12) held in Cambridge, UK, in 2011.Masashi Yanagisawa, MD PhD, is an
Investigator of the Howard Hughes
Medical Institute (HHMI) and Patrick
E. Haggerty Distinguished Professor of
Molecular Genetics at the University
of Texas Southwestern Medical Center
at Dallas. Since 2010, he doubles as
Professor and Director of the Interna-
tional Institute for Integrative Sleep
Medicine at the University of Tsukuba.
Dr. Yanagisawa discovered endothelins,their receptor and processing enzymes, and demonstrated their roles in
the embryonic development. Later he also discovered the orexins and
their receptors, molecules that regulate sleep and wakefulness. Promis-
ing therapeutic applications have emerged from both of his lines of ex-
ploratory research. Dr. Yanagisawa is a member of the US National
Academy of Sciences, and member of the International Advisory Board
of the International Conferences on Endothelin. He was honorary chair
of the Tenth International Conference on Endothelin (ET-10) held in
Bergamo, Italy, in 2007, the Eleventh International Conference on
Endothelin (ET-11) held in Montréal, Canada, in 2009, and the Twelfth
International Conference on Endothelin (ET-12) held in Cambridge, UK,
in 2011.Local Organizing Committee and International Scientiﬁc Advisory
Board Members
Dennis L. Andress, MD, is the Senior Med-
ical Director for Renal Development with
Abbvie. Prior to his employment at
Abbvie, he was Clinical Professor of Medi-
cine andDirector of theRenal Dialysis Unit
at the Division of Nephrology, University
of Washington, Seattle, WA. Dr. Andress
contributed basic and clinical research
discoveries related to complications of
chronic kidney disease and end-stage
renal failure with over 100 publications
in peer-reviewed journals. His research
the National Institutes of Health and the
n. His current interest is in drug develop-Northwest Kidney Foundatio
ment for diabetic nephropathy particularly as it relates to the endothelin
system and to the selective ETA receptor antagonist, atrasentan.Kazutaka Aonuma, MD PhD, is the Pro-
fessor and Director of Tsukuba University
Hospital
Education
1971–1977 University of
Yamaguchi, School of Medicine,
Yamaguchi; M.D.
1977–1982 Post Graduate School of
Medicine, Tokyo Medical and Dental
University, Tokyo; Ph.D.
Cardiology, Miami Heart Institute, Miami1982–1984 Fellowship in
Beach, Florida, USA.
Academic Appointment
1999–present: VisitingProfessor of Cardiology,Departmentof Internal
Medicine, Tokyo Medical and Dental University of Medicine, Tokyo, Japan
2001–present: Visiting Professor of Internal Medicine, St. Marianna
University School of Medicine, Kanagawa, Japan
2002–present: Visiting Professor of Internal Medicine, Tokai
University School of Medicine, Kanagawa, Japan
2006–present: Professor and Director of Cardiovascular Division,
University of Tsukuba, Tsukuba, Japan
Board Certiﬁcation:
Council Member of the Japanese Society of Electrocardiography
Council Member of the Japanese Heart Rhythm Society
Council Member of the Japanese Clinical Cardiac Electrophysiology
Society
Council Member of the Japanese Circulation Society
Member of the American Heart Association
Editors of the Journal
Circulation Journal Associate Editor
Journal of Cardiology Associate Editor
Journal of Arrhythmia Editor in ChiefAnna Bagnato, PhD, has been a group lead-
er in the Laboratory ofMolecular Pathology
at the Regina Elena National Cancer Insti-
tute of Rome, Italy, since 1998. She is the
author of numerous articles published in
leading international journals and book
chapters and has coordinated cancer re-
search grants by public and private agen-
cies. Her research, deﬁning many critical
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of cancer, in particular in ovarian carcinoma model, represents the
translational basis leading to the introduction of novel targeted thera-
pies in the ovarian cancer management. As a member of the Board of
the Italian Cancer Society, Dr. Bagnato plays an active role in promoting
cancer research and communicating science to the public.Brian D. Cain, PhD, studied at the Universi-
ty of Colorado and the University of Illinois
(Ph.D., 1983). While a postdoctoral fellow
at Stanford University, he began a continu-
ing study of the F1F0 ATP synthase. Dr.
Cain joined the faculty of the University of
Florida in 1988. He has chaired the Physical
Biochemistry Study Section for theNIH, and
the Bioenergetics Gordon Conference.
In collaboration with Dr. Charles Wingo
and later Dr. Michelle Gumz (UF, Dept. ofMedicine), the Cain laboratory has also investigated themolecular regula-
tion of ion transport in the renal distal collecting duct. Microarray exper-
iments showed high level induction of the Edn1 gene in a collecting duct
cell line (mIMCD-3) in response to aldosterone leading to our interest in
endothelin. Hormone treatment resulted in binding of both the mineral-
ocorticoid and glucocorticoid receptors to a hormone response element
located in the 5′ regulatory region of the Edn1 gene. Recently, the
miRNA landscape of mIMCD-3 cells was determined by microarray anal-
ysis. Ongoing experiments are aimed at determining the mechanisms of
miRNA regulation of Edn1 expression.Carmine Cardillo,MD, is a professor of In-
ternal Medicine, head of a Division of Inter-
nal Medicine and chief of the Vascular
Physiology Laboratory at the Catholic Uni-
versityMedical School in Rome, Italy. He re-
ceived his M.D. and his fellowship in
Internal Medicine from the Catholic Univer-
sity. He also served for almost 4 years as a
Visiting Scientist at the Cardiology Branch,
NHLBI, of the National Institutes of Health
in Bethesda, MD, USA.In addition to practicing and teaching, Dr. Cardillo has been involved
for long time in research on the mechanisms of vascular dysfunction in
patients with risk factors for cardiovascular disease. In particular, he has
studied changes in the main endothelial homeostatic mechanisms,
including the nitric oxide pathway and the endothelin system, in hyper-
tension, diabetes and hypercholesterolemia. He has also investigated
the determinants of impaired vasoactive properties of insulin in condi-
tions like obesity and the metabolic syndrome. He has authored almost
one hundred peer-reviewed articles on these topics.Subrata Chakrabarti, MBBS, PhD, FRCPC,
is a Professor and Chair of the Department
of Pathology at the University of Western
Ontario, London, Ontario, Canada. He also
works as a pathologist at the LondonHealth
Sciences Centre biology. Dr. Chakrabarti in-
vestigates mechanisms of chronic diabetic
complications and studies diabetic retinop-
athy, nephropathy and diabetic heart dis-
ease and has published extensively in this
ﬁeld. He has a long-standing interest in the
role of endothelins in chronic diabetic com-
plications and other diseases.Martine Clozel, MD, Actelion Pharma-
ceuticals, Ltd, Allschwil, Switzerland
Martine Clozel, a pediatrician specialized
in neonatal intensive care, obtained her
MD degree at Nancy University, France,
and received further training in physiol-
ogy and pharmacology from McGill Uni-
versity, Montreal, and the University of
California, San Francisco. During her
11 years at F. Hoffmann-La Roche Ltd,
she initiated the research project onendothelin and endothelin receptor antagonists (ERAs) which led to the
discovery and clinical development of bosentan (Tracleer), tezosentan,
clazosentan and macitentan. Her group has published over 150 peer-
reviewed papers in the ﬁelds of endothelial function, endothelin and
ERAs. In 1997 she was awarded the Hoffmann-La Roche Research Prize
for her achievements in the ﬁeld of endothelin research. In 1997 she co-
founded Actelion Pharmaceuticals Ltd, where she is Senior Vice President
and since 2009, Chief Scientiﬁc Ofﬁcer. Martine Clozel is a member of the
Scientiﬁc Editorial Board of Science Translational Medicine. In 2008, she
was honored as “Chevalier dans l'Ordre de la Legion d'Honneur”.Michael R. Dashwood, PhD, obtained his
Ph.D. in Physiology at the University of
London in 1986 having previously been
at the National Institute for Medical Re-
search in London where his original re-
search was investigating central sites of
opioid induced analgesia and cardiovas-
cular control. For the last 20 years his
focus has shifted from brainstem regions
involved in central cardiovascular control
to the ‘local’ vascular effects ofendothelium-derived nitric oxide and endothelin. These studies have
generated a number of research papers, reviews and book chapters de-
scribing the potential involvement of these factors in diseases including
atherosclerotic vascular disease such as critical limb ischemia and ve-
nous disease including vein graft failure.Jo G. R. De Mey, PhD, is a Professor of
Medical Molecular Pharmacology at
the Institute of Molecular Medicine,
University of Southern Denmark, and
professor of Vascular Pharmacology at
the Cardiovascular Research Institute
Maastricht (CARIM) of Maastricht
University, the Netherlands. He was
trained as a zoologist (M.Sc.) and as a
pharmacologist (Ph.D.) at the Univer-
sity of Antwerp. Before joining Maas-tricht University he headed a cardiovascular department in
pharmaceutical industry focusing on therapeutic applications of na-
triuretic peptides. He is the author of more than 160 scientiﬁc arti-
cles covering early aspects of endothelium-dependent vascular
reactivity, endothelial dysfunction in hypertension, endothelium de-
pendent arterial remodeling in experimental models of heart failure
and diabetes and, more recently, molecular pharmacology of ET-
receptors and endogenous functional antagonists of ET-receptor
function such as CGRP. He coordinates the cardiovascular research
within the Dutch public–private partnership Top Institute Pharma that
addresses among others “metalloproteases and novel targets in endo-
thelial dysfunction”.
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‘Bean’) is a clinical and academic ne-
phrologist in Edinburgh, Scotland. His
clinical interests are immune-mediated
renal disease especially vasculitis and
high-risk renal transplantation. He jointly
runs the South-East Scotland Vasculitis &
Lupus Clinic. His research is both laborato-
ry and clinical in nature and has focused on
the vascular aspects of chronic kidney dis-
ease, particularly the role of ET-1.Adviye ErgulMD PhD, FAHA, is a Profes-
sor of Physiology at the Georgia Health
Sciences University in Augusta, GA. She re-
ceived her Ph.D. in Biochemistry and Mo-
lecular Biology on a project related to
endothelin-1 (ET-1) structure and func-
tion. Since then she has been interested
in the physiology/pathophysiology of the
ET system. Shemade the seminal observa-
tion that plasma ET-1 concentrations are
much higher in African-American hyper-tensives which contributed signiﬁcantly to our understanding of the ET
system in salt-sensitive hypertension. She built a strong research career
on the roles of ET and its receptors in diabetes-associated complications.
She has published more than 100 scientiﬁc papers and her research has
been continuously supported by the American Heart Association,
AmericanDiabetesAssociation, National Institutes ofHealth andVeterans
Administration. Dr. Ergul is a Fellow of the American Heart Association.Keiichi Fukuda, MD PhD, is a professor of
Department of Cardiology, Keio University
School of Medicine in Tokyo, Japan. One of
his research interests was the role of
endothelin on the cardiovascular develop-
ment, especially its effect on cardiac sym-
pathetic innervation. He discovered that
cardiomyocyte-produced nerve growth
factor (NGF) mediated cardiac sympathet-
ic nerve innervation, and NGF productionfrom cardiomyocytes was determined by autocrine/paracrine secreted
endothelin I-mediated signals. Moreover, cardiac sympathetic nerve
transdifferentiated to cholinergic neurons during heart failure via
gp130 mediated signals, especially LIF. He is also interested in regener-
ative medicine, and developed various techniques for induction, puriﬁ-
cation, and transplantation of cardiomyocytes obtained from ES cell/iPS
cells. He also investigated the disease model of iPS cells obtained from
the patients with hereditary heart disease such as long QT syndrome
and Brugada syndrome.Adel Giaid, MD PhD, currently a Professor of
Cardiology at the McGill University Health Cen-
tre in Montreal, Canada. He was of the pioneers
who began to investigate the pathological role
of endothelin in the cardiopulmonary system.
Indeed, Dr. Giaidwas theﬁrst to report the pres-
ence of endothelin in the fetal and adult nervous
and respiratory systems. He then reported an
association between the pathological character-
istics of pulmonary artery disease (pulmonary
hypertension) and expression of endothelin-1.Subsequently, he demonstrated increased expression of endothelin-1 in
a number of diseased conditions such as pulmonary ﬁbrosis, heart
failure, atherosclerosis and pulmonary neoplasm.Hunter C. Gillies, MD, is a Senior Director
in clinical research at Gilead Sciences Inc.,
San Francisco. He spent the past 13 years
in the pharmaceutical industry working
on clinical drug development, primarily
focusing on the cardiovascular effects
of phosphodiesterase type 5 inhibitors
(PDE5i) and endothelin receptor antago-
nists (ERA). For the past eight years has
worked in the ﬁeld of pulmonary hyper-
tension including clinical research andtrials in PAH and PH secondary to chronic lung disease. Currently his re-
search focus involves clinical trials involving new pharmacological tar-
gets and exploring the potential for pharmacological synergy between
PDE5i and ERAs. He has a number of peer reviewed publications on car-
diovascular physiology and pharmacology, exercise physiology and the
development of PD5i for cardiopulmonary disorders.Anil Gulati, MD PhD, FCP, is a Professor of
Pharmaceutical Sciences and Associate
Dean for Research at theMidwestern Uni-
versity. He is a United States Fulbright
Scholar 2008–2009 and winner of Inter-
national Ranbaxy Research Award 2007.
He obtained his M.D. in 1982 from King
George's Medical College, Lucknow, India
and became Diplomate American Board
of Clinical Pharmacology (1992). He was
awarded a Ph.D. in 1996 by Erasmus Uni-versity Rotterdam, The Netherlands. He is a Fellow of the American Col-
lege of Clinical Pharmacology. He has more than 265 peer reviewed
publications and guided research of more than 70 graduate students
and research fellows. Dr. Gulati has 21 patent applications (six issued
patents) and has founded three companies. Medications developed by
Dr. Gulati are undergoing clinical trials in the United States and India.Ken-ichi Hirata, MD PhD, is a Professor of
Cardiovascular Medicine at the Kobe Uni-
versity Graduate School of Medicine. His
research has focused on atherosclerosis
and coronary circulation. He is speciﬁcally
interested in vascular biology, including
inﬂammation, immune system and endo-
thelial function to develop novel therapies
for atherosclerotic diseases. Dr. Hirata is
a member of Japanese Circulation Society,
Japanese Atherosclerosis Society, ESC and
the AHA.
Berthold Hocher, MD, studiedmedicine
in Berlin and Heidelberg. He started his
research career at theDepartment of Bio-
chemistry at the Free University of Berlin
where he also accomplished his Ph.D. In
the following years he worked clinically
in the ﬁeld of internal medicine with
the focus on endocrinology and nephrol-
ogy. After clinical posts at the Benjamin
Franklin University Hospital of the Free
62 Conference Faculty, Session Chairs, and Invited SpeakersUniversity of Berlin and theCharite, he became senior consultant nephrol-
ogist and associated professor at the University Hospital Bern/
Switzerland. Thereafter, he worked in the pharmaceutical industry in
pre-clinical and clinical drug development (Solvay Pharmaceuticals, Han-
nover, Germany and Roche, Basel, Switzerland). Currently he holds a full
professorship at the University in Potsdam for experimental nutritional
medicine and is a visiting professor at the Jinan University, Guangzhou,
China. Themain topics of his research group are fetal programming of car-
diovascular diseases, exploration of novel targets for the treatment of di-
abetic complications focusing on diabetic nephropathy as well as
biomarker research.Satoshi Homma, MD PhD, is a Professor of
Cardiovascular Medicine at the University
of Tsukuba. His research interest, since the
Ph.D. work in Tsukuba (1987–1991), has
focused on the hemo-dynamic changes in
microcirculation of visceral organs, inﬂu-
enced by some potent vaso-active sub-
stances such as endothelin, prostacyclin,
phospho-diesterase inhibitor, nitroglycer-
ine, CGRP, etc. After his clinical career that
started at the National Cardiovascular Cen-ter in Osaka (1992–1998), he returned as a medical staff in the critical
care unit here in the University of Tsukuba Hospital and has begun to
develop the treatment of patients with pulmonary hypertension, con-
sidering the effects of the potent vaso-active substances on the patient
body and its microcirculation. Dr. Homma is also interested in the qual-
ity of the hospital care. He is now involved in working as director of
QARM (Quality Assurance and Risk Management) department at the
University Hospital and as councilor of the Japanese Society of Quality
and Safety in Healthcare.Uichi Ikeda, MD PhD, is Professor and
Chairman of the Department of Cardiovas-
cular Medicine at Shinshu University
School of Medicine in Matsumoto City, Na-
gano Prefecture. His research has focused
on cardiac regeneration and angiogenesis.
He is also interested in epidemiology, vas-
cular function and cell biology, and thera-
peutics of peripheral artery disease. He
has also published several reports
concerning pathophysiological roles ofendothelin in Takayasu's arteritis, valvular heart disease and coronary
artery disease.Hiroshi Ito, MD PhD, is the Professor of
Cardiovascular and Respiratory Medicine,
Akita University Graduate School of Med-
icine. He was also appointed as the Direc-
tor of Akita University Hospital and the
Vice President of Akita University. His re-
search interest is the pathophysiology of
heart failure, especially, focused on roles
of neurohumoral factor in the mecha-
nisms of heart failure. He is also involved
in several clinical researches in heart fail-ure. He is a committee board member of the Japanese Circulation Soci-
ety, and member of several scientiﬁc societies related to
cardiovascular diseases.Hiroshi Ito, MD PhD, FACC, FESC is Profes-
sor of CardiovascularMedicine at Okayama
University Graduate School of Medicine in
Okayama, Japan. He is an executive board
member of the Japanese Circulation Socie-
ty and of Japanese Pulmonary Circulation
Society. He is going to be the chairman of
3rd annual scientiﬁc meeting of Japanese
Pulmonary Circulation Society in 2014. He
is the chairman of working group on “Indi-cation and application of balloon pulmonary angioplasty to patients
with chronic pulmonary thromboembolism” that is supported by the
Japanese Circulation Society. His research interests include clinical ap-
plication of echocardiography and development of therapeutic strategy
of heart failure. In the ﬁeld of pulmonary hypertension, he studies the
mechanisms of right ventricular dysfunction associated with pulmo-
nary hypertension with echocardiography.Masaaki Ito, MD PhD, is Professor of Cardi-
ology and Nephrology at Mie University
Graduate School of Medicine and
Physician-in-Chief of Cardiology in Mie
University Hospital in Tsu, Japan. He has
beenworking on the regulation of contrac-
tile cycle in vascular smooth muscle. He
discovered the signal transduction regard-
ing Ca2+ sensitization of smooth muscle
contraction through Rho-kinase-mediatedmyosin phosphatase inhibition. He is also interested in clinical pharma-
cology in hypertension and coronary atherosclerosis. He is recently
going to have research-activities focusing on clinical and basic research
on pulmonary hypertension and right heart failure. Dr. Ito is a Fellow of
Japanese College of Cardiology and the Japanese Society of Hyperten-
sion, and a member of the Japanese Circulation Society and the
American Heart Association.Yasuki Kihara, MD PhD, FJSIM, FACC,
FACP, FESC
1987–1989, Instructor in Medicine,
Harvard Medical School, Boston
1989–1993, Assistant Professor, Toya-
maMedical andPharmaceuticalUniversity
1993–2004, Assistant (-2002) and As-
sociate (-2004) Professor, Department of
CardiovascularMedicine, KyotoUniversity
Graduate School of Medicine
2005–2007, Chairman, Department of
Cardiovascular Medicine, Kobe General Hospital
2008–present, Professor and Chairman, Department of Cardiovascular
Medicine, Hiroshima University Graduate School of Biomedical & Health
SciencesCheMyong Jay Ko, PhD, is an Associate
Professor of the Department of Compara-
tive Bioscience, College of Veterinary
Medicine at the University of Illinois at
Urbana-Champaign (UIUC). He graduated
from the Seoul National University in
Seoul, Korea, with a bachelor degree in
Biology education in 1986. Dr. Ko taught
Biology and General Science for a few
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at the Seoul National University where studied Developmental Biology
and Biology Education. In 1998, he graduated with a Ph.D. degree, and
moved to United States to do a postdoctoral training at the University
of Kentucky in the ﬁeld of reproductive biology and molecular endocri-
nology. In 2002, he took an Assistant Professor position in the Depart-
ment of Clinical Sciences and Department of Biology at the University
of Kentucky. In 2011, he moved to the University of Illinois at Urbana
Champaign to take his current academic position. Hismajor research in-
terests are in female reproductive biology.Theoﬁlos M. Kolettis, MD, after gradua-
tion from the German School of Athens,
obtained his MD degree from Medical
School, University of Athens in 1984 and
his Ph.D. in 1991. He trained in Cardiology
at the Edinburgh Royal Inﬁrmary, U.K. and
at the AthensGeneral Hospital. Heworked
as a clinical research associate at the De-
partment of Electrophysiology, Eastern
Heart Institute, NJ, and as an attending
physician at the Onassis Cardiac SurgeryCenter, Athens, Greece. He is currently a Professor in Cardiology at the
University of Ioannina, Greece. Dr. Kolettis practices in the ﬁeld of cardi-
ac pacing and clinical electrophysiology. His research interests include
the study of the pathophysiological effects of endothelin during
myocardial infarction, focusing on ventricular remodeling and
tachyarrhythmias.Issei Komuro, MD PhD FAHA, FISHR, is a
Professor of Medicine and Chairman of
Cardiovascular Medicine Department,
The University of Tokyo Graduate School
of Medicine. After obtaining MD and Ph.D.
from The University of Tokyo, he started
postdoctoral fellowship at HarvardMedical
School in 1989. He has become professor of
Chiba University in 2001, of Osaka Univer-
sity in 2009 and of The University of
Tokyo in 2012, and PI of CREST in 2011.His research interests are molecular mechanisms of heart failure,
cardiovascular development and regeneration. He has published over
500 papers in peer-review journals and received many awards including
Outstanding Investigator Prize from ISHR, Sato award from JCS and Balz
award. He is an associate editor of Circulation Research and an editorial
boardmember of Journal of Clinical Investigation, Arteriosclerosis Throm-
bosis andVascular Biology, Cardiovascular Research and Journal ofMolec-
ular Cellular Cardiology.Takeyoshi Kunieda, MD PhD FCCP, is a
Professor of Medicine, International Uni-
versity, Health and Welfare, Clinical
Medical Research Center, KakenHospital,
Ichikawa, Chiba, Japan, and former Pro-
fessor of Medicine, Keio University. Pro-
fessor Kunieda graduated from Keio
University, Tokyo, Japan in 1962 and
completed Ph.D. from Keio University in
1968 and has been studying pulmonary
circulation for more than 40 years, most-ly involved in the study of pulmonary hypertension and pulmonary em-
bolism at the National Cardiovascular Center, Osaka, and KeioUniversity, and worked together with many specialized doctors for
the treatment of pulmonary hypertension. He currently is a chairman
of the Japanese Society of Pulmonary Hypertension Research.Hiroki Kurihara, MD PhD, is a Professor of
Molecular and Cellular Biology at the Uni-
versity of Tokyo Graduate School of Medi-
cine. He contributed to the discovery of
endothelin in 1988 and ﬁrst reported
endothelin-1 knockout mice in 1994.
His present research interests are cranio-
facial and cardiovascular development
and the involvement of neural crest cells.
He also acts as a member of Institute for
Biology and Mathematics of Dynamical
Cell Processes (iBMath), the Universityof Tokyo, to promote a relationship between medicine and
mathematics.David Langleben, MD, is a Professor in the
McGill University Faculty of Medicine, and
former Chief of Cardiology of the Jewish
General Hospital. He founded and directs
the Center for Pulmonary Vascular Disease,
the ﬁrst pulmonary hypertension clinic in
Canada. His research interests include
lung vascular metabolism; behavior and
function of lung vascular cells; vascular
cell biology; epidemiology of pulmonary
hypertension, and the developmentof new medications for pulmonary hypertension. His work has been
supported by the Medical Research Council of Canada, The Canadian
Institutes for Health Research, the Fonds de la Recherche en Sante du
Quebec, the Heart and Stroke Foundations of Quebec and Canada, and
the Quebec Lung Association.Marilena Loizidou, PhD, a Senior Lecturer
in the Division of Surgery and Interven-
tional Science, UCL, UK. The division is sit-
uated on 4 different campuses and
Marilena is Head of the Royal Free Cam-
pus. She originally trained in biochemistry
(Canada) and pharmacology (UK). Her
long term research has focused on epithe-
lial–stromal interactions in cancer and
translational cancer pharmacology. In co-
lorectal cancer, she investigated tumori-genic actions of endothelin-1. Her group systematically delineated
anti-cancer mechanisms of endothelin A receptor antagonists, mainly
through cancer–stroma interactions. The antagonists are now in colo-
rectal cancer trials. She currently leads the cancer nanotechnology
group which uses nanoparticles and nanoformulations to improve can-
cer imaging and drug efﬁcacy. Her current research focuses on (a) novel
drug nanoformulations, including photochemical internalization and
(b) using biofunctionalized (targeted) nanoparticles for theranostics.
Dr. Loizidou is also the Director of the MSc in Surgical Science and Co-
Director and Founder of the MSc in Nanotechnology and Regenerative
Medicine — cited in Nature as a most innovative course, 2009. Dr.
Loizidou is a council member of the Society of Academic and Research
Surgery, UK and was voted as UCL Academic Role Model (2013).
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the Department of Cardiovascular Medi-
cine, Nagasaki University Graduate School
of Biomedical Sciences, and Chief of Cardi-
ology of Nagasaki University Hospital, Na-
gasaki City, Japan. He graduated from
Faculty of Medicine, the University of
Tokyo in 1986. After trained as a resident
and clinical fellow in Tokyo University
Hospital, he started research under the
supervision of Hiroki Kurihara, MD, Ph.D.He was involved in the projects regarding Edn1 deﬁciency mice and
Edn1 overexpressing mice. His present major interests are cardiovascu-
larmedicine, vascular biology, atherosclerosis, and chronobiology. He is
an executive board member of The Japanese Vascular Biology andMed-
icine Organization, and an editorial board member of Arteriosclerosis
Thrombosis Vascular Biology.Janet Maguire, PhD, is a Senior Research
Associate in the Clinical Pharmacology
Unit, University of Cambridge and a Fellow
of Queens' College, Cambridge. She is a
member of the BHF Receptor Research
Group whose focus is the pharmacology of
established and novel G-protein coupled re-
ceptors in the human cardiovascular system
and who have particular expertise in the
endothelin peptides and their receptors.
Dr. Maguire has co-authored ﬁfty eightpeer reviewed papers, eight book chapters and seventeen reviews, and
is Editor and contributor of a volume, ‘Peptide Research Protocols:
Endothelin’ for Humana Press. She is also involved in undergraduate
and graduate teaching in pharmacology, supervising pre-clinical medical
and veterinary students, is a Wellcome Trust/MRC 4-year Ph.D. program
Principal Investigator and a member of the International Union of Phar-
macology Receptor Nomenclature Sub-Committee on Endothelin
Receptors.Hiromi Matsubara, MD PhD, is currently
the Director of Department of Clinical Sci-
ence and Division of Cardiology at Nation-
al Hospital Organization Okayama
Medical Center, Okayama, Japan. After
receiving his MD from Okayama Uni-
versity Medical School and ﬁnishing
his residency in internal medicine at
the National Okayama Hospital, he
began his fellowship at the National
Cardiovascular Center, Osaka, Japan in1990. He became an Assistant Professor at the Department of Phys-
iology II at Okayama University Graduate School of Medicine and
Dentistry in 1993. He then became an Assistant Professor of De-
partment of Cardiovascular Medicine in 1997 and again promoted
in 2000 to the Associate Professor of Cardiovascular Medicine. He
then became the Director of Division of Cardiology at National Hos-
pital Organization Okayama Medical Center and he also serves as
the Director of Department of Clinical Science since 2010.
His investigative interests have focused on clinical and physio-
logic aspects of pulmonary hypertension. He has made Division of
Cardiology at National Hospital Organization Okayama Medical
Center as one of the largest pulmonary hypertension center in
Japan.Yasuo Matsumura, PhD, is a Professor of
Pharmacology at OsakaUniversity of Phar-
maceutical Sciences (Takatsuki, Japan)
since 2002. Professor Matsumura is a
member of council of the Japanese Phar-
macological Society, Japanese Society for
Circulation Research, Nitric Oxide Society
of Japan, etc. Hewas amember of Editorial
Staff (2007–2010) of Folia Pharmacologica
Japonica, an ofﬁcial journal of The Japanese
Pharmacological Society.He obtained hisPh.D. degree (1987) at the Osaka City University Medical School. His
main areas of expertise, research andwork include renal, heart, and circu-
latory pharmacology, health food science, and vascular biology.Soichi Miwa, MD PhD, is a Professor of the
Department of Cellular Pharmacology, Hok-
kaido University Graduate School of Medi-
cine in Sapporo, Japan. He was an associate
of Professor Tomoh Masaki in the Depart-
ment of Pharmacology, Kyoto University
Graduate School of Medicine in Kyoto,
Japan, from 1992 to 1997, and a Secretary
General of the Fifth International Conference
on Endothelin (ET-5; President, Tomoh
Masaki) held in Kyoto, Japan. His researchfor over two decades has focused on intracellular Ca2+ signaling mediat-
ed by endothelin receptor, especially in terms of receptor-operated Ca2+
channels and store-operated Ca2+ channels. He is also involved in a re-
search on regulatory mechanisms for G-protein coupled receptor
(GPCR) recycling/degradation using ETA andETB receptors as amodel sys-
tem. His immediate hope is to clarify the molecular mechanism for the
different fates of ETA and ETB receptors following ET stimulation. Recently
he is also interested in a pathophysiological role of ET system in the devel-
opment of insulin resistance as a major cause of type 2 diabetes mellitus.Shin-ichi Momomura, MD is a Professor of
Cardiovascular Medicine and also the Presi-
dent of Jichi Medical University Saitama
Medical Center. His specialty is heart failure
and had participated in publishing Japanese
Guidelines for Acute Heart Failure as well as
Japanese Guidelines for Chronic Heart Failure.
Hismain interest in heart failure researchwas
cardiac function in diseased heart. However,
recently it is shifting to sleep disordered
breathing and cardiovascular disease. He wasappointed as Chairman of the Committee of JapaneseGuidelines for theDi-
agnosis and Treatment of Sleep Disordered Breathing Associated with Car-
diovascular Disease which was published in 2010. He is now conducting a
randomized study to evaluate the effect of adaptive servo-ventilation on
left ventricular function in patientswith heart failure due to left ventricular
systolic dysfunction.He is the President of the 2013Annual ScientiﬁcMeet-
ing of the Japanese Heart Failure Society held in Saitama City in November.Toyoaki Murohara, MD PhD, FESC is a
Professor at the Department of Cardiology,
Nagoya University Graduate School of
Medicine. He obtained M.D. and Ph.D. de-
grees at Kumamoto University School of
Medicine. Hecompleted a Postdoctoral Fel-
lowship at Thomas Jefferson University in
1993, followed by theDepartment of Cardi-
ology, St. Elizabeth's Medical Center, Tufts
University School of Medicine, Boston, in
65Conference Faculty, Session Chairs, and Invited Speakers1996. His research interests are vascular biology for the prevention of
atherosclerosis and regeneration therapy for ischemic diseases. He is
an Associate Editor of Circulation Journal and Hypertension Research,
and an Editorial Board Member of Circulation Research, Journal of the
American College of Cardiology, Journal ofMolecular and Cellular Cardi-
ology and ATVB.Norifumi Nakanishi, MD PhD, is a Director
of Endowed Department of Pulmonary Hy-
pertension and Pulmonary Vascular Medi-
cine, National Cerebral and Cardiovascular
Center Research Institute, Osaka, Japan. His
clinical and research interests are in pulmo-
nary arterial hypertension and chronic
thromboembolic pulmonary hypertension.
Dr Nakanishi is a councilor of the Japanese
Society for Adult Congenital Heart Disease
and serves as an executive board memberof Japanese Pulmonary Hypertension Society. He is also themain editor
of Guideline for Treatment of Pulmonary Hypertension of the Japanese
Circulation Society.Kazuwa Nakao, MD PhD, is a Professor at
the Medical Innovation Center, Kyoto Uni-
versity Graduate School of Medicine. Prior
to holding the current title, he was Profes-
sor and Chairman of the Department of
Medicine and Clinical Science, Kyoto Uni-
versity Graduate School of Medicine
(Kyoto, Japan) for twenty years. He was
also Director of Kyoto University EBM Re-
search Center, Kyoto University Translation-
al Research Center, and Vice Dean of KyotoUniversity Graduate School ofMedicine. He has been engaged in Transla-
tional Research for natriuretic peptides (ANP, BNP and CNP) and leptin,
has achieved clinical application of these hormones and has authored
925 English publications in the areas of Cardiovascular Endocrinology,
and Metabolism and Obesity/Metabolic Syndrome. Dr. Nakao is the
President of Japan Society for the Study of Obesity (JASSO) and a former
Chair of the Board of Directors at the Japan Endocrine Society (JES). He
has received numerous awards including the Edwin Von Baelt Award
(1988), Medical Award (The Japan Medical Association, 2004), The
Prize for Science and Technology, Research Category, The Commenda-
tion for Science and Technology (Minister of Education, Culture, Sports,
Science, and Technology, Japan, 2008), the Takeda Medical Award
(Takeda Science Foundation, 2009), and Medal with Purple Ribbon
(2011).John Pernow, MD PhD, FESC, is a Professor
and Head of the Cardiology Unit, Depart-
ment of Medicine, Karolinska Institutet,
Stockholm, Sweden. He is also senior con-
sultant of cardiology at the Department of
Cardiology, Karolinska University Hospital.
He is a member of the scientiﬁc council of
the Swedish Heart and Lung Foundation.
His research is focused on mechanisms be-
hind and treatment targeting endothelialdysfunction with special emphasis on the role of endothelin in cardio-
vascular disease. John Pernow has been active in endothelin researchfor twenty years and published several papers regarding the pharma-
cology and pathophysiological role of endothelin in cardiovascular dis-
ease and complications to diabetes. An additional research area is
protection againstmyocardial ischemia and reperfusion injury in exper-
imental and clinical studies. Dr. Pernow is a Fellow of the European Soci-
ety of Cardiology.Jennifer S. Pollock, PhD, the Weiss Profes-
sor and Director of the University System
of GeorgiaMD/Ph.D. ProgramatGeorgia Re-
gents University. She earned her Ph.D. in Bi-
ological Chemistry from The University of
North Carolina at Chapel Hill and received
post-doctoral training under the tutelage
of Dr. Ferid Murad, 1998 Nobel Laureate in
Physiology and Medicine. Subsequent to her
post-doctoral training, she worked as a
Drug Discovery Scientist at Abbott Laborato-ries before moving to GRU in 1995. Dr. Pollock's research is on the vascu-
lar and renal mechanisms of hypertension and diabetes focusing on the
role of nitric oxide and endothelin in the relationship of stress on the
vasculature, renal function, and immune responses. Her research is cur-
rently supported by two Program Project Grants from the National In-
stitutes of Health. Dr. Pollock serves as a member of two AHA study
sections and as an ad-hoc reviewer for NIH Program Project Grants.
Dr. Pollock has mentored and trained over 60 undergraduate students,
medical students, graduate students, post-doctoral fellows, clinical fel-
lows, and junior faculty members in her tenure at GRU.Sunu B. Raharjo, MD PhD, is a physician-
scientist at the National Cardiovascular
Center Harapan Kita/Department of Car-
diology & Vascular Medicine, University
of Indonesia. As a physician, he has been
working as cardiologist and cardiac elec-
trophysiologist, taking care of patients
and teaching students on a daily basis;
while as a scientist, he has been working
with other scientists in his Cardiovascular
Research Center to continue his researchinterests. Dr Raharjo's scientiﬁc work began with studies on the molec-
ular aspects of endothelin converting enzyme family, and continued
with translational researches using animal models. He performed
these two research area when he was a Ph.D. student and a JSPS Post-
doctoral Fellow at Kobe University, Kobe, Japan. There, he worked
with Professor Emoto to apply pharmacological as well as genetic inter-
ventions to investigate the pathophysiological roles of endothelin (and
bradykinin) system in animal models. Returning to Jakarta, Indonesia,
Dr Raharjo resumed his cardiology training. Besides, his passion on re-
search brought him to continue his basic and translational research in
the clinical area. He has beenworking on the role of endothelin and bra-
dykinin in metabolic syndrome and pulmonary hypertension.Yoshihiko Saito, MD, FAHA, is a Professor
of the First Department of Internal Medi-
cine at Nara Medical University in
Kashihara, Japan. His research has focused
on roles of humoral factors in the cardio-
vascular system, especially heart failure.
He demonstrated the usefulness of
ANP infusion for the treatment of heart
failure in 1987, only 3 years after ANP dis-
covery. He is now the president of the
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another scientiﬁc society focusing natriuretic peptides, adrenomedullin,
ghrelin, endothelin and other cytokines. He held the international sym-
posium on CVEM in Nara in 2010. Recently he has become speciﬁcally
interested in the underling molecular mechanism of the cardiorenal
connection.Tsutomu Saji,MD PhD, Professor in Pedi-
atrics, has worked in the ﬁeld of pediatric
cardiology for over 30 years. Since 1976,
after the graduation from Toho University,
Tokyo, he started off his career as amedical
intern in the Department of Pediatrics,
Toho University Hospital, then became an
Assistant Professor (1986), an Associate
Professor (1993), and then a Professor in
Chief in Pediatrics (1997–present). Healso has experience as an intern in Pediatric Cardiology, Heart Institute
of Japan, Tokyo Women's Medical College, (1977–1978), and a research
fellow in Children's Hospital of Los Angeles, University of Southern Cali-
fornia, CA, U.S.A. (1987–1988). Dr. Saji has expertise in pulmonary hy-
pertension, Kawasaki vasculitis, and myocarditis in children. He serves
as FAHA, International Liaison of CVDY in AHA, FACC, FSCAI (the Society
for Cardiac Angiography and Interventions), FJCC, the Secretary General
of the Japanese Society of Ped Card, President of Japanese Pediatric Pul-
monary Circulation Society, and holds numerous important roles in
many different scientiﬁc societies and associations in Japan. He also par-
ticipated in the Japanese Guideline Committees on PAH as a committee
member. Dr. Saji reported several genetic studies on BMPR2, ALK1,
ALK6, and Smad8 mutation, and negative HHV-8 in PAH.Satoshi Sakai, MD PhD, is an Assistant
Professor at the Department of Cardiovas-
cular Medicine, University of Tsukuba in
Tsukuba, Japan. After his training as a car-
diologist in Tsukuba University Hospital,
he started basic studies under the supervi-
sion of Professor Katsutoshi Goto and Pro-
fessor TakashiMiyauchi in Tsukuba, Japan.
He won the YIA of the 4th International
Conference on Endothelin (ET-4, London)
in 1995 for the pathophysiological role ofmyocardial endothelin system on the development of heart failure. He
conducted his postdoctoral fellowship at Baylor College of Medicine in
Houston, Texas; he moved back to Tsukuba and he leads his own labora-
tory as physician–scientist. Dr. Sakai's research deals with mechanisms
and treatment of heart failure, pulmonary hypertension, and cardiopul-
monary interrelations from the viewpoints not only of the endothelin sys-
tem but also of the inﬂammation and metabolism. Dr. Sakai is a council
member of Japanese Pharmacological Society, Japanese Heart Failure
Society, and Japanese Pulmonary Circulation Society, and serves as a Sec-
retary General of The Thirteenth International Conference on Endothelin
(ET-13).Shigetake Sasayama, MD, is an Emeritus
Professor of Kyoto University and currently
an honorary director of Uji Hospital in
Kyoto. Dr. Sasayama was the Chief Director
of the Japanese Circulation Society from
2000 to 2002. He has also served as the
Chief Director of the Japanese Heart Failure
Society and is the past president of the
Japanese Society of Internal Medicine.
From 2002 to 2005, he committed himselfin the WHF as a board member representing Asia-Paciﬁc region. He
has a longstanding interest in physiological and biological mechanisms
of the development of heart failure. He has also pioneered in an assess-
ment of functional capacity of heart failure patients. Over the past
35 years, he has contributed more than 600 original articles to the car-
diovascular literature and has publishedmore than 50 invited articles or
book chapters. He also serves as editor or on the editorial board of many
major international and domestic journals in Cardiology, including the
ofﬁcial journal of the American Heart Association, “Circulation”.Toru Satoh, MD PhD
1982: Graduated from Keio University
School of Medicine
1982–86: Internal Medicine Residency
in Keio University School of Medicine
1986–89: Cardiology Fellow at Keio
University School of Medicine
1989–92: Vice Chief in Cardiology in
Ashikaga Red Cross Hospital
1992–94: Cardiologist at Kawasaki
Medical School
1994–99: Cardiologist at the division of Pulmonary Circulation in
National Cardiovascular Center in Japan
1999–2008: Assistant Professor in Cardiology and Associated Profes-
sor in Medical Education at Keio University School of Medicine
2009–: Professor in Cardiology at Kyorin University School of
Medicine
A leading doctor/ scientist in pulmonary hypertension in Japan.
Member of the working group in the 5th world symposium on pulmo-
nary hypertension.
Specialty: pulmonary hypertension, general cardiology, cardiac
physical examination, exercise physiology, medical education.Ernesto Schiffrin, MD PhD, FRSC, FRCPC,
FACP, FAHA, is Physician-in-Chief of the Jew-
ish General Hospital and holds a Canada Re-
search Chair in Hypertension and Vascular
Research.He is Professor andVice-Chair (Re-
search), Department of Medicine, McGill
University. Dr. Schiffrin's research deals
with mechanisms and treatment of high
blood pressure, from molecules and cells to
humans. He is author of more than 500
peer-reviewed publications, many bookchapters and is editor of 2 published books, and 2 in preparation, on mo-
lecular and clinical aspects of vascular disease and hypertension. Dr.
Schiffrin has been President of the Canadian Hypertension Society
(1991–92), Chair of the High Blood Pressure Research Council of the
AmericanHeart Association (2002–2004), President of the InterAmerican
Society ofHypertension (2005–2007) andPresident of theQuebecHyper-
tension Society (2009–2011). Dr. Schiffrin has been Vice-President
(2010–2012) and is now President of the International Society of Hyper-
tension (2012–2014). Dr. Schiffrin has been Associate Editor of Hyperten-
sion (AHA journal) since 2003. Dr. Schiffrin received the Senior
Investigator Award of the Canadian Society of Internal Medicine in 2003
and the Distinguished Service Award of the Canadian Hypertension Soci-
ety in 2004. Hewas elected Fellow of the Royal Society of Canada in 2006,
and received the 2007 Irvine Page-Alva Bradley Lifetime Achievement
Award of the High Blood Pressure Research Council of the American
Heart Association and the 2010 Bjorn Folkow Award of the European So-
ciety of Hypertension. He was appointed Member of the Order of Canada
(C.M.) in July 2010.Hewas awarded the2011ExcellenceAward inHyper-
tension Research of the American Heart Association, in September 2011.
In 2013 he was awarded the Queen Elizabeth II Diamond Jubilee Medal.
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sor of Cardiology at TohokuUniversity. Dr.
Shimokawa is interested in the mecha-
nisms for coronary atherosclerosis and
vasospasm. He was the ﬁrst to develop
an animal model of coronary vasospasm
and to demonstrate the involvement of
Rho-kinase in the pathogenesis of the
spasm and atherosclerosis both in ani-
mals and humans. Based on these ﬁnd-
ings, a speciﬁc Rho-kinase inhibitor hasbeen developed and now in clinical trials for pulmonary hypertension.
Dr. Shimokawa is also interested in endothelium-derived relaxing fac-
tors (EDRFs), especially endothelium-derived hyperpolarizing factor
(EDHF). He has demonstrated the mechanism for endothelial dysfunc-
tion in atherosclerosis and the beneﬁcial effect of ﬁsh oils and
eicosapentaenoic acid on endothelial function. He has identiﬁed that en-
dothelium-derived hydrogen peroxide (H2O2) is an EDHF in animals
and humans, which notion is widely accepted. Dr. Shimokawa is also in-
terested in applying the recent advances in biomedical engineering to
vascular medicine. This includes the development of extracorporeal
shock wave therapy for severe ischemic heart disease, and shock wave
ablation system for arrhythmias. Finally, Dr. Shimokawa has been
conducting several large-scale clinical trials on heart failure, ischemic
heart disease, and pulmonary hypertension as principal investigators.Francesca Spinella, PhD, graduated in
Biology from the University of Catania
in 1995, and obtained her Ph.D. degree
in Neurobiology from the sameUniversi-
ty in 1999. As Ph.D. student she has
worked in professor De Vellis' laboratory
in Los Angeles, CA. She is currently a se-
nior investigator at the Regina Elena Na-
tional Cancer Institute of Rome where
she has been working on endothelins
since 2001. As a research fellow fundedby the Italian Association for Cancer Research (AIRC; 2002–2004), she
has been working in Dr. Anna Bagnato's laboratory in Rome studying
the role of endothelins on the cell–cell interaction and communication
on melanoma cells. Of particular interest is the analysis of signal trans-
duction pathways through which ET-1 triggers cancer progression,
with special attention on the role of ET-1 in promoting angiogenesis
and tumor cell invasive behavior. In 2010 shewas Principal Investigator
in a project funded by AIRC in which she deﬁnedmany critical activities
of ET-1 in the induction of lymphangiogenesis. Currently, Dr Spinella's
research is focused on the study of mechanism by which blocking
ETBR could lead to tumor angiogenesis and lymphangiogenesis reduc-
tion, as potentially candidate in the inhibition of hematic- and
lymphatic-driven metastatization.Pierre-Louis Tharaux, MD PhD
INSERM Research Professor
Professional Experiences
2009–present: Inserm Research Profes-
sor and group leader, Inserm Paris Cardio-
vascular Research Center (PARCC), Hopital
Europeen Georges Pompidou, Paris, France
Education and Training
– Medical studies at FaculteNecker-Enfants
Malades- Universite Paris Descartes– Interne des Hopitaux de Paris (1991) (resident and fellow)
– Fellowship in Nephrology (1991–1998). Nephrology: Board Certiﬁed
(1998)– Medical Doctorate from Universite Paris Descartes (1998)
– Ph.D. in Physiology & Pathophysiology fromUniversite Pierre &Marie
Curie (2000)
– Curriculum inphysiology andpathophysiology of sleep and cardiovas-
cular disorders, Universite Paris Sud (2000)
Scientiﬁc interests: Pathophysiology of the Renal Circulation
Research in our laboratory is centered on the analysis of mouse vas-
cular and renal pathophysiology, with a particular emphasis on genes
implicated in signaling pathways. Our work covers three areas:
1- G-proteins coupled receptors (GPCRs) and tyrosine kinase receptors
(TKR) signaling in podocytes in response to immune vasculitis
withrapid-progressive glomerulonephritis (RPGN), diabetic ne-
phropathy and in focal-segmental glomerulosclerosis(FSGS).
2- Signaling in podocytes and endothelial cells insickle cell nephropa-
thy and vasculopathy and
3- Immunopathogenesis of sickle cell diseaseRita C. Tostes, PhD, is currently a Professor at
the School ofMedicine of Ribeirao Preto, Uni-
versity of São Paulo, a researcher at the Na-
tional Council for Scientiﬁc and
Technological Development (CNPq) and a
member of the Foundation for Research Sup-
port of the State of São Paulo (FAPESP). He
holds the degrees of B.Sc. in Pharmacy, Uni-
versity of São Paulo (1990), M.Sc. (1993)
and Ph.D. (1996) in Biological Sciences
(Pharmacology, School of Medicine of
Ribeirao Preto, University of São Paulo). He
had internships at the Albert Einstein Collegeof Medicine. NY, University of Montreal, Clinical Research Institute of
Montreal and Georgia Regents University (Medical College of Georgia),
GA. He has scientiﬁc interests in the ﬁeld of Cardiovascular Pharmacology
and Physiology, focusing on the signaling pathways that control vascular
function and its changes in hypertension, diabetes and erectile dysfunc-
tion. His speciﬁc interests are on the role of endothelin, aldosterone, cyto-
kines and glycosylationwithN-acetylglucosamine (O-GlcNAc) in vascular
(dys)function.Ivana Vanĕčková, PhD, was born in Prague,
Czech Republic. She graduated at the
Charles University in 1987. She followed
her postgraduate studies at the Institute of
Physiology, Czech Academy of Sciences,
where she obtained her Ph.D. Degree for
the Thesis “Age-dependent changes in the
function of isolated perfused kidney in vari-
ous forms of experimental hypertension in
the rat”. She started as a Postdoctoral Fellow
at the renal physiology laboratory at the In-
stitute of Physiology, Prague. In 2001 shebecame the Assistant Research Professor at the Department of Experi-
mental Medicine, Institute for Clinical and Experimental Medicine,
Prague, where she was Head of the Department for Experimental Hy-
pertension. As a Senior Investigator she continued herwork in the Insti-
tute of Physiology AS CR, in the Department of Experimental
Hypertension, where she is a Deputy Head. She is a member of
American Society of Physiology, European Society of Hypertension and
International Society of Hypertension. Most important topics of her
work: mechanisms of contribution of renin–angiotensin system and
endothelin systems to blood pressure regulation.
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biology at the University Paul Sabatier in
Toulouse, France and at the Georg August
University in Gottingen, Germany as an
ERASMUS Programme fellow. He obtained
his master in Pharmacology and
Pharmacochemistry from the University
Louis Pasteur in Strasbourg, France in 2005.
He joined the group of Professors Franz
Theuring and Berthold Hocher within theCenter for Cardiovascular Research of the ChariteMedical School of Berlin,
Germany as a fellow of theMarie Curie Host Fellowship for Early Stage Re-
search Training program CARDIOVASC funded by the European Commis-
sion. He obtained his Ph.D. in natural sciences from the Free University
of Berlin, Germany in 2010. He next moved to Japan and joined the re-
search group of Professor Noriaki Emoto in the Department of Clinical
Pharmacy at the Kobe Pharmaceutical University as a postdoctoral fel-
low. His research interests include the understanding of the role of the
endothelin system in renal and cardiovascular diseases (heart failure,
hypertension, diabetic nephropathy…). His publicationsmostly present
basic research and pre-clinical studies using various genetically modi-
ﬁed mice. Nicolas Vignon-Zellweger is Secretary General of the Thir-
teenth International Conference on Endothelin.Bambang Widyantoro, MD PhD, gradu-
ated from University of Indonesia. He
joined residencyprogram in the Cardiolo-
gy Department, University of Indonesia
and has been working at the National
Cardiovascular Center, Harapan Kita Hos-
pital in Jakarta since 2003. During this pe-
riod, he spent ﬁve years completing the
research work of his Ph.D. thesis investi-
gating the role of endothelin in cardiovas-
cular medicine under the supervision ofhis mentor, Professor Noriaki Emoto of Kobe University, Japan. His cur-
rent interests as a clinical cardiologist and researcher include hyperten-
sion, heart failure and diabetes-related cardiovascular disease.Keiko Yamauchi-Takihara, MD PhD, is
Presidential Aide and Director of Health
Care Center in Osaka University, and the Pro-
fessor of Department of CardiovascularMed-
icine, Osaka University Graduate School of
Medicine. She worked in the laboratory of
Dr. MJ Sole at The Center for Cardiovascular
Research, The Toronto Hospital, as a post-
doctoral fellow, where she began learning
molecular cardiology. In 1992, she became
Assistant Professor in the Department ofMolecular Medicine, Osaka University Graduate School of Medicine,
conducting researchon signal transductionof cytokines andgrowth factors
in cardiacmyocytes. Current research interests include pathophysiology of
heart failure, pulmonary circulation and cardiopulmonary interrelations.eakers
Matthias Barton, MD, FAHA, is a graduate
of Hannover Medical School, Germany,
and has been Professor of Cardiology at
the University of Zurich in Switzerland
since 2007. He received his clinical training
in internal medicine, cardiology, and anes-
thesiology at Hannover Medical School
and the University Hospitals of Basel, Bern,
and Zurich. From1999, he held a SCORECa-
reer Development Award from the SwissNational Science Foundation to study novel factors involved in coronary
artery disease and has a clinical interest in preventive cardiology. For
the past 25 years, his research has focussed on atherosclerosis and the
molecularmechanisms and endothelial factors contributing to coronary
artery disease and cardiovascular risk. Dr. Barton is a Fellow of the
AmericanHeart Association and amember of the International Advisory
Board of the International Conferences on Endothelin. He is Past Chair of
the Twelfth International Conference on Endothelin (ET-12) held in Cam-
bridge, UK, in 2011, and served as Guest Editor of the ET-12 Conference
Proceedings, Endothelin XII.Ariela Benigni, PhD, read Biological Sci-
ence (Biol. Sci. D. Degree, University of
Milan). She researched problems of anti-
cancer and anti-thrombotic drugs in
Milan and in Strasbourg before joining
the Mario Negri Institute for Pharmacolog-
ical Research in Bergamo, Italy, where she
studied mediators of renal damage includ-
ing the role of endothelin-1 in progressive
renal injury (Ph.D. Degree, University of
Maastricht). She is currently the Head ofDepartment of Molecular Medicine and Scientiﬁc Secretary of Mario
Negri Institute for Pharmacological Research of Bergamo. Dr. Benigni
has contributed to more than 230 research publications. Her recent
work has looked at therapies to halt renal disease progression or even
induce regression of kidney lesions by multidrug approach with the in-
terest to characterize cellular determinants of kidney repair after angio-
tensin II blockade. Dr. Benigni acted as Associate Editor of Kidney
International, Journal of Nephrology and International Journal of Artiﬁ-
cial Organs; actually she is Editor of Expert Opinion on Therapeutic Pat-
ents and PeerJ. She was consultant of WHO for a multicenter
observational study on the predictive ability of angiogenic factors for
Pre-eclampsia. For this latter study shehas been appointed as Senior Fel-
low by the University of Oxford, Nufﬁeld Department of Obstetrics & Gy-
naecology. She was the Chairman of the 10th International Conference
on Endothelin (ET-10), held in Bergamo 2007. Dr. Benigni has recently
been named to take part in the Visiting Committee of AERES – Agence
d’'Évaluation de la Recherche et de l’'Enseignement Supèrieur – for the
evaluation of scientists at the Hôpital Necker in Paris and she received
the Merit Award of Bergamo City Hall for her contribution to science.Anthony Davenport, PhD, directs the
Human Receptor Research Group in the
Clinical Pharmacology Unit, University of
Cambridge focusing on understanding the
role of G-protein coupled receptors, and
their transmitters in the human cardiovas-
cular system and how these are altered
with disease. The role of endothelin in
human pathophysiology, especially the de-
velopment of atherosclerosis has been a
major research interest since the discoveryof the peptide in 1988. These include quantifying and imaging
endothelin receptors in normal and diseased human tissue with sub-
type selective radioligands and antisera as well as positron emission to-
mography to non-invasively image endothelin receptors in vivo. Wider
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